Pharma BD Deal Intelligence

Chugai Pharmaceutical Co., Ltd. / Araris Biotech AG

2025 · Licensing/Option · $780M · Complete

Araris Biotech and Chugai Pharmaceutical announced a research collaboration and option-to-license agreement on January 8, 2025. Araris will apply its AraLinQ linker-conjugation platform to generate novel antibody-drug conjugates using Chugai antibodies against undisclosed targets. If Chugai exercises its option, Araris is eligible for approximately USD 780 million in milestone payments plus royalties. The upfront payment was not disclosed. Chugai subsequently exercised the option on February 10, 2026.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals